Navigation Links
Alnylam in Medical News

PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study

MONTEREY, Calif., Dec. 13 /PRNewswire/ -- PARI's eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial. Results of the Phase I trial were announced today at the 18th Annual Drug Delivery to the Lungs meeting held in Edi...

Isis to Receive $4.6 Million From Alnylam

CARLSBAD, Calif., May 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) as its portion of the upfront fees in the recently announced transaction between Takeda P...

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference

...axis of delayed graft function after kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling precl...

aTyr Pharma Raises an Additional $12 Million

...ng and leading many successful biotechnology companies, including Alkermes, alnylam Pharmaceuticals, Cubist Pharmaceuticals, Momenta Pharmaceuticals and Sirtri...ealth Services, Advanced Inhalation Research, Akamai Technologies, Allaire, alnylam Pharmaceuticals, American Superconductor, Aspect Medical Systems, Avici Sys...

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call

... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

I-Therapeutix, Inc. Closes $15 Million Financing

...companies. Polaris-backed successes in life sciences include Adnexus (sold to Bristol-Myers Squibb), Advanced Inhalation Research (sold to Alkermes), alnylam Pharmaceuticals (ALNY), Glycofi (sold to Merck), Momenta Pharmaceuticals (MNTA), and Transform Pharmaceuticals (sold to Johnson & Johnson). Curren...

Isis Pharmaceuticals to Present at Jefferies' 3rd Annual Healthcare Conference

... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit

...ed by Quark through the gene discovery platform BiFAR(TM). For the structure of these products, Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in IND-enabling nonclinical studies a...

Isis Pharmaceuticals to Present at Needham's 8th Annual Life Sciences Conference

... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...
Alnylam in Medical Technology

PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study

MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients. ALN-RSV01 is a RNAi therapeutic being developed as a treatment for respiratory syncytial virus (RSV...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... Isis received a $375,000 milestone payment from alnylam for initiation of clinical trials on ALN-VSP. ... Isis earned milestone payments from Archemix and alnylam because each company advanced drugs that incorpora...e-stranded RNA interference (ssRNAi) technology to alnylam as part of a new strategic initiative to continue ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Isis and Collaborators Present New Research at the ATVB Annual Conference

... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Quark Pharmaceuticals Presents at Asia TIDES Conference

...ery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling precli...

Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

...rom acute injury. QPI-1002 is a chemically modified siRNA discovered by Quark with structure covered under licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1002 was the first systemically administered siRNA in a human clinical study. About Quark Pharmaceuticals, Inc. Quark ...

Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema

...mmencement of the trial triggers a milestone payment to Quark from Pfizer, a small percentage of which is payable by Quark to Silence Therapeutics and alnylam as technology license milestone payments. The Phase II prospective, randomized, dose-ranging study is evaluating the safety and efficacy of PF-45236...

Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss

...llular integrity. The AHLi-11 active molecule was designed and patented by Quark. The Company has licenses for certain RNAi intellectual property from alnylam and Silence Therapeutics About Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on disc...

Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity

...oday publication of a study in the journal Cell by alnylam and Stanford University scientists on the role of ...ntigen recognition is poorly understood. Recently, alnylam scientists and collaborators have discovered a new...es, including cancer and viral infections. About alnylam ...

Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

...Officer. He further added that Calando has filed for patent protection on several siRNA duplexes against the RRM2 target and has licensed patents from alnylam Pharmaceuticals to enable it to develop and commercialize an RNAi therapeutic against this target. Further information about Calando can be found at...
Alnylam in Biological News

Mechanism for the in-vivo transport of siRNA

...ying mechanisms remained obscure. Markus Stoffel, ETH Zurich Professor at the Institute for Molecular Systems Biology, together with chemists from the alnylam Company, has now succeeded in elucidating the mechanism for the uptake of siRNA in combination with fatty acids in mammals. The corresponding paper, w...
Alnylam in Biological Technology

Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call

CARLSBAD, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: New findings published in the journal Nature on the role of a microRNA, known as miR-21, in heart failure When: Monday, December 1, 2...

Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer

...r of companies achieve outstanding success. Among them are: Accordant Health Services, Acusphere, Advanced Inhalation Research (acquired by Alkermes), alnylam Pharmaceuticals, Aspect Medical Systems, Cubist Pharmaceuticals, deCODE genetics, GlycoFi (acquired by Merck), Momenta Pharmaceuticals and TransForm P...

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

...ery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclin...

Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University

... Biotechonomy, Nobel Laureate Phil Sharp of MIT , Microsoft Startup Labs Managing Director Reed Sturtevant, Boston Power CEO Christina Lampe-Onnerud, alnylam Pharmaceuticals CEO John Maraganore, Boston Scientific Co-founder John Abele, and Yet-Ming Chiang, co-founder of A123Systems. Start-ups represent...

Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting

... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting

...eutics); Christina Gamba-Vitalo, Senior Director Preclinical Development at alnylam Pharmaceuticals (topic: Progress in developing siRNAs as drugs); and Patric...ure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary struct...

Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day

... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

The IN VIVO Blog Selects First Annual 'Deal of the Year'

... medical device industries, have selected a Deal of the Year for 2008 -- alnylam Pharmaceuticals' RNA interference alliance with Takeda Pharmaceuticals . ... example of how it pulls off this impressive feat." "The deal allows alnylam to end the year with approximately $500 million in cash and sets the RNAi p...

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

...development of microRNA-based therapeutics for hepatocellular carcinoma has been transferred to Regulus Therapeutics. Regulus, a joint venture between alnylam Pharmaceuticals and Isis Pharmaceuticals focused on the development of microRNA-based therapeutics, and Rosetta Genomics will continue collaborating u...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

...bsidiaries including: -- $2.0 million milestone payment from Bristol-Myers Squibb for a PCSK9 development candidate -- $4.6 million from alnylam Pharmaceuticals, Inc. -- $1.4 million from Antisense Therapeutics Limited -- $3.3 million from Ibis representing a 72% increase from second half o...
Other Tags
(Date:8/2/2014)... Dr. Ping Hu is a worldly ... in Medicine from the Capital Medical University in Beijing, ... Medical Microbiology from the University of London. She ... Sciences Center and finished her fellowship at the University ... was active both inside and outside of the classroom ...
(Date:8/2/2014)... August 02, 2014 When the Black Hat ... 2nd this year, one thing can be always counted on, ... known as fear, uncertainty and doubt. The run-up has ... this article published by Reuters on July 31st about ... mouse or keyboard to successfully infect a system with malware, ...
(Date:8/1/2014)... (PRWEB) August 02, 2014 The successful ... the stamping business of Guangdong FODAY Automobile Co.,LTD. As ... the company had already organized an excellent team to ... number of detailed, in-depth technical plans. The company’s vice ... were in the direct involvement of the specific arrangement ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Cannabis use among ... teens aged 14 to 17 having used marijuana at least ... With their slogan “Say ‘No’ to Drugs, Say ‘Yes to ... reaching out to youth this summer with factual information about ... past six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ ...
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
Breaking Medicine News(10 mins):Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2
(Date:7/31/2014)... biomass burning burning forests to create agricultural ... agriculture and wildfires figures into both climate ... release of a new study by Stanford University ... the degree of that contribution had never been ... paper published July 30 in the Journal ...
(Date:7/31/2014)... Kansas State University researchers have completed a 20-year ... Flint Hills prairie at different times of the ... current late spring time frame has no measurable ... may have multiple benefits. , The study was ... Konza Prairie Biological Station fire chief, and Joseph ...
(Date:7/31/2014)... people make a rational choice to be liberal or ... it a matter of genetics?, Two political scientists from ... University say that neither conscious decision-making nor parental upbringing ... lean right. , A growing body of evidence shows ... core of political differences, the researchers say in the ...
Breaking Biology News(10 mins):Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3Scientists find growing consensus: Political attitudes derive from body and mind 2
Other Contents